Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the 2023 Milken Institute Future of Health Summit. According to the announcement, Cybin CEO Doug Drysdale is slated to participate on a panel about innovations in mental health care; the title of the panel is “Revolutionizing Mental Health Care through Innovation.” The event is scheduled for Nov. 7, 2023, in Washington DC. The Milken Institute is a nonprofit, nonpartisan think tank dedicated to connecting resources and innovation so the best ideas can succeed. This year’s conference will focus on the most significant issues affecting medical research, preventative care, and public health. “It is an honor to be part of such an important gathering of leading medical experts and scientists,” said Cybin CEO Doug Drysdale in the press release. The panel is scheduled to begin at 9 a.m. ET. “Sadly, there has been little recent progress in addressing the mental health treatment gap and limited effectiveness of current standards of care. This Summit is a welcome opportunity to exchange ideas and foster innovation as we tackle the current mental health crisis. We are encouraged by our positive interim results showing an unprecedented improvement in depressive symptoms, which could potentially offer therapeutic benefits to help address the current mental health crisis. We look forward to talking about our innovative work at the Milken Summit.”
To view the panel discussion, visit https://ibn.fm/05SiC
To view the full press release, visit https://ibn.fm/NroIE
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental-health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN